Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 27, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals

SAN DIEGO, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
December 01, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Receives Nasdaq Compliance Notice

SAN DIEGO, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
November 29, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences to Present at the 9th Annual LD Micro Main Event

SAN DIEGO, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
November 18, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Provides Update on Vitaros NDA Following Receipt of FDA Feedback

SAN DIEGO, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
November 08, 2016 16:01 ET | Source: Apricus Biosciences

Apricus Biosciences Provides Corporate Update and Third Quarter Financial Results

Strategic Focus on Growing Global Vitaros® Revenue and Achieving Profitability in 2017Apricus Granted Type B Meeting with FDA to Discuss the Vitaros® U.S. NDA Re-SubmissionConference Call / Webcast...
November 02, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Corporate Update and Third Quarter 2016 Financial Results Conference Call

SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
October 26, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Greece

SAN DIEGO, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
October 20, 2016 16:30 ET | Source: Apricus Biosciences

Apricus Biosciences Announces 1-for-10 Reverse Stock Split

SAN DIEGO, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced a...
October 12, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences to Present at the 2016 BIO Investor Forum

SAN DIEGO, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
September 28, 2016 19:00 ET | Source: Apricus Biosciences

Apricus Biosciences Closes $3.7 Million Registered Direct Offering

SAN DIEGO, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right